We completely stay away from biotechs...just too many variables. I am sure there are some very big potential plays out there, but we just wont touch em.
When we invested in GENE, the DNA wave was breaking, they had key IP and they became a licensing machine. Mgmt's ridiculous salaries and their focus on a breast cancer test kit changed our love for the company.
News 
Market Data 
Discover 
